Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. 1990

C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
Oncology Department Hôpital Pitié-Salpêtrière, Paris, France.

A total of 42 patients with cerebral metastases of malignant melanoma were included in this study of the nitrosourea fotemustine. The treatment plan consisted of a l-h i.v. infusion of 100 mg/m2 fotemustine every week for 3-4 weeks, followed by a 4- to 5-week rest period. Responding or stabilised patients then received 100 mg/m2 fotemustine every 3 weeks. Among the 39 evaluable patients, 2 complete responses and 9 partial responses were documented, leading to an overall response rate of 28.2%. Most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis. Toxicity was mild and mainly hematological, especially in patients previously treated by polychemotherapeutic regimen. Our study confirms the activity of fotemustine in cerebral metastases of disseminated malignant melanoma.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
February 1992, American journal of clinical oncology,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
January 1990, Cancer chemotherapy and pharmacology,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
September 1992, Melanoma research,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
April 1967, The Ohio State medical journal,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
September 1978, La Nouvelle presse medicale,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
February 2003, Melanoma research,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
January 1991, European journal of cancer (Oxford, England : 1990),
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
February 2003, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
June 1999, Journal of neuro-oncology,
C Jacquillat, and D Khayat, and P Banzet, and M Weil, and M F Avril, and P Fumoleau, and M Namer, and J Bonneterre, and P Kerbrat, and J J Bonerandi
February 1975, Cancer,
Copied contents to your clipboard!